Insider filing · LAB

Casdin Partners Master Fund, L.P. bought $636K of Standard Biotools (LAB)

Executed Sep 3 2025, disclosed Sep 5 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Sep 5 2025), the stock returned +4.7% (delay-adjusted); from the execution session (Sep 3 2025), +6.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

CP Casdin Partners Master Fund, L.P. Director profile →

Casdin Partners Master Fund, L.P. (Director) filed 6 Form 4 reports as a reporting entity in the trailing twelve months (5 purchases, 1 sale), most often in LAB. Across 5 priced purchase filings, the average 21-session return was +14.0% from execution and +12.5% from disclosure (delay-adjusted; derived). The largest single filing was $28.1M of BLFS (1,200,000 sh across 3 lots, as filed), executed May 19.

LAB LAB LAB · 10 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→